North America’s medical devices industry saw a rise of 10.11% in deal activity during March 2021, when compared with the last 12-month average, led by Hellman & Friedman’s $1bn acquisition of Cardinal Health, according to GlobalData’s deals database.

  • Embed this chart

    Embed this chart into your website

    Copy and paste the image source into your website to display the chart.

 

A total of 98 medical devices industry deals worth $4.89bn were announced for the region in March 2021, against the 12-month average of 89 deals.

Of all the deal types, venture financing saw most activity in March 2021 with 64 transactions, representing a 65.3% share for the region.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

In second place was M&A with 26 deals, followed by private equity deals with eight transactions, respectively capturing a 26.5% and 8.2% share of the overall deal activity for the month.

In terms of value of deals, M&A was the leading category in North America’s medical devices industry with $2.41bn, while venture financing and private equity deals totalled $1.3bn and $1.18bn, respectively.

North America medical devices industry deals in March 2021: Top deals

The top five medical devices deals accounted for 55.8% of the overall value during March 2021.

The combined value of the top five medical devices deals stood at $2.73bn, against the overall value of $4.89bn recorded for the month.

The top five medical devices industry deals of March 2021 tracked by GlobalData were:

1) Hellman & Friedman’s $1bn private equity deal with Cardinal Health

2) The $695m acquisition deal with Resolution Bioscience by Agilent Technologies

3) Agiliti’s $475m acquisition of Northfield Medical

4) The $320m acquisition of Asuragen by Bio Techne

5) Organon &’s acquisition of Alydia Health for $240m.